Literature DB >> 35854963

Reticular epithelial edema after penetrating keratoplasty in a patient taking netarsudil.

Lauren J Jeang1, Ankit S Shah1, Jon D Hammer1, Sonal S Tuli1.   

Abstract

Netarsudil is a relatively new medication for the treatment of primary open-angle glaucoma and ocular hypertension. It has been associated with red eyes and burning after instillation. Reticular epitheliopathy is a relatively rare complication of netarsudil that has been described in patients with preexisting corneal edema. We report the case of a healthy 76-year-old woman who developed reticular epitheliopathy after full-thickness penetrating keratoplasty that completely resolved following discontinuation of the medication. In cases where netarsudil is initiated for treatment of glaucoma or, off-label, endothelial dysfunction, reticular epithelial edema should be considered in patients complaining of a decline in vision and severe pain.
Copyright ©2022. All rights reserved. Reproduction in whole or in part in any form or medium without expressed written permission of the Digital Journal of Ophthalmology is prohibited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35854963      PMCID: PMC9255647          DOI: 10.5693/djo.02.2022.02.002

Source DB:  PubMed          Journal:  Digit J Ophthalmol        ISSN: 1542-8958


  19 in total

1.  Corneal Hemorrhage Associated with Netarsudil in the Setting of Corneal Neovascularization.

Authors:  Samuel Asanad; Rebecca Zhang; Osamah J Saeedi
Journal:  Ophthalmol Glaucoma       Date:  2020 Sep - Oct

2.  Effect of the Rho Kinase Inhibitor Y-27632 on Corneal Endothelial Wound Healing.

Authors:  Naoki Okumura; Ryota Inoue; Yugo Okazaki; Shinichiro Nakano; Hiroko Nakagawa; Shigeru Kinoshita; Noriko Koizumi
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-09       Impact factor: 4.799

3.  Organized migration of epithelial cells requires control of adhesion and protrusion through Rho kinase effectors.

Authors:  Ann M Hopkins; A'drian A Pineda; L Matthew Winfree; G Thomas Brown; Mike G Laukoetter; Asma Nusrat
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-11-30       Impact factor: 4.052

4.  Reticular Bullous Epithelial Edema in Corneas Treated with Netarsudil: A Case Series.

Authors:  C Ellis Wisely; Katy C Liu; Divakar Gupta; Alan N Carlson; Sanjay G Asrani; Terry Kim
Journal:  Am J Ophthalmol       Date:  2020-04-11       Impact factor: 5.258

5.  Reticular Corneal Edema or Corneal Honeycombing in Eyes Treated With Netarsudil: A Case Series.

Authors:  Khaled Moumneh; Arsham Sheybani; Ronald L Fellman; David G Godfrey; Davinder S Grover
Journal:  J Glaucoma       Date:  2020-07       Impact factor: 2.503

6.  Reversible Corneal Endothelial Abnormalities With Netarsudil.

Authors:  Angelo P Tanna; Hamed Esfandiari; Kyla Teramoto
Journal:  J Glaucoma       Date:  2020-06       Impact factor: 2.503

Review 7.  New therapeutic modality for corneal endothelial disease using Rho-associated kinase inhibitor eye drops.

Authors:  Noriko Koizumi; Naoki Okumura; Morio Ueno; Shigeru Kinoshita
Journal:  Cornea       Date:  2014-11       Impact factor: 2.651

8.  Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).

Authors:  Janet B Serle; L Jay Katz; Eugene McLaurin; Theresa Heah; Nancy Ramirez-Davis; Dale W Usner; Gary D Novack; Casey C Kopczynski
Journal:  Am J Ophthalmol       Date:  2017-12-01       Impact factor: 5.258

9.  Netarsudil-associated epithelial keratopathy.

Authors:  Meera S Ramakrishnan; Victoria M Addis; Amanda Y Lehman; Prithvi S Sankar
Journal:  Am J Ophthalmol Case Rep       Date:  2020-06-28

10.  Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension.

Authors:  Inder P Singh; Robert D Fechtner; Jonathan S Myers; Terry Kim; Dale W Usner; Hayley McKee; Huan Sheng; Richard A Lewis; Theresa Heah; Casey C Kopczynski
Journal:  J Glaucoma       Date:  2020-10       Impact factor: 2.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.